2015 05 v.8 371-374
中国骨质疏松性骨折诊疗指南(骨质疏松性骨折诊断及治疗原则)
基金项目(Foundation):
邮箱(Email):
DOI:
中文作者单位:
中国医学科学院北京协和医学院北京协和医院骨科;四川大学华西医院骨科;重庆医科大学附属第一医院骨科;解放军总医院骨科;卫生部北京医院骨科;苏州大学附属第一医院骨科;哈尔滨医科大学附属第二医院骨科;
摘要(Abstract):
<正>1概述骨质疏松症是一种全身性、代谢性骨骼系统疾病,其病理特征为骨量降低、骨微细结构破坏、骨脆性增加,骨强度下降,易发生骨折。与年龄、性别、种族等因素密切相关,绝经后妇女多发。骨折是骨质疏松症最严重的后果,常是骨质疏松患者的首发症状和就诊原因。骨质疏松症分为原发性和继发性,本指南所指的骨折是原发性骨质疏松症导致的骨折。
关键词(KeyWords):
| 3,720 | 532 | 66 |
| 下载次数 | 被引频次 | 阅读次数 |
参考文献
[1]Wang G,Yang H,Chen K.Osteoporotic vertebral compression fractures with an intravertebral cleft treated by percutaneous balloon kyphoplasty.J Bone Joint Surg Br,2010,92(11):1553-1557.
[2]Mao H,Zou J,Geng D,et al.Osteoporotic vertebral fractures without compression:key factors of diagnosis and initial outcome of treatment with cement augmentation.Neuroradiology,2012,54(10):1137-1143.
[3]胡侦明,杨惠林,王根林,等.经皮椎体成形术治疗的相关建议.中华骨与关节外科杂志,2015,8(5):375-376.
[4]Parker M,Johansen A.Hip fracture.BMJ,2006,333(7557):27-30.
[5]L?nnroos E,Kautiainen H,Karppi P,et al.Incidence of second hip fractures.A population-based study.Osteoporos Int,2007,18(9):1279-1285.
[6]Black DM,Delmas PD,Eastell R,et al.Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.N Engl J Med,2007,356(18):1809-1822.
[7]Black DM,Reid IR,Boonen S,et al.The effect of 3 versus6 years of zoledronic acid treatment of osteoporosis:a randomized extension to the HORIZON-Pivotal Fracture Trial(PFT).J Bone Miner Res,2012,27(2):243-254.
[8]Black DM,Reid IR,Cauley JA,et al.The effect of 6 versus9 years of zoledronic acid treatment in osteoporosis:a randomized second extension to the HORIZON-Pivotal Fracture Trial(PFT).J Bone Miner Res,2015,30(5):934-944.
[9]Lyles KW,Colón-Emeric CS,Magaziner JS,et al.Zoledronic acid and clinical fractures and mortality after hip fracture.N Engl J Med,2007,357(18):1799-1809.
[10]Black DM,Schwartz AV,Ensrud KE,et al.Effects of continuing or stopping alendronate after 5 years of treatment:the Fracture Intervention Trial Long-term Extension(FLEX):a randomized trial.JAMA,2006,296(24):2927-2938.
[11]Bone HG,Hosking D,Devogelaer JP,et al.Ten years'experience with alendronate for osteoporosis in postmenopausal women.N Engl J Med,2004,350(12):1189-1199.
[12]Zhang ZL,Liao EY,Xia WB,et al.Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women:a 6-month,randomized,open-label,active-comparator-controlled study with a6-month extension.Osteoporos Int,2015,26(9):2365-2374.
[13]Black DM,Thompson DE,Bauer DC,et al.Fracture risk reduction with alendronate in women with osteoporosis:the Fracture Intervention Trial.J Clin Endocrinol Metab,2000,85(11):4118-4124.
[14]Neer RM,Arnaud CD,Zanchetta JR,et al.Effect of parathyroid hormone(1-34)on fractures and bone mineral density in postmenopausal women with osteoporosis.N Engl J Med,2001,344(19):1434-1441.
[15]Fahrleitner-Pammer A,Langdahl BL,Marin F,et al.Fracture rate and back pain during and after discontinuation of teriparatide:36-month data from the European Forsteo Observational Study(EFOS).Osteoporos Int,2011,22(10):2709-2719.
[16]Chen JF,Yang KH,Zhang ZL,et al.A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia.Osteoporos Int,2015,26(1):11-28.
[17]Iwamoto J,Seki A,Sato Y,et al.Vitamin K2 promotes bone healing in a rat femoral osteotomy model with or without glucocorticoid treatment.Calcif Tissue Int,2010,86(3):234-241.
[18]Cockayne S,Adamson J,Lanham-New S,et al.Vitamin K and the prevention of fractures:systematic review and metaanalysis of randomized controlled trials.Arch Intern Med,2006,166(12):1256-1261.
[19]Huang ZB,Wan SL,Lu YJ,et al.Does vitamin K2play a role in the prevention and treatment of osteoporosis for postmenopausal women:a meta-analysis of randomized controlled trials.Osteoporos Int,2015,26(3):1175-1186.
[20]Lyritis GP,Paspati I,Karachalios T,et al.Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures.A double blind,placebo-controlled clinical study.Acta Orthop Scand Suppl,1997,275:112-114.
[21]Tsakalakos N,Magiasis B,Tsekoura M,et al.The effect of short-term calcitonin administration on biochemical bone markers in patients with acute immobilization following hip fracture.Osteoporos Int,1993,3(6):337-340.
[22]朱汉民,邱贵兴,李梅,等.原发性骨质疏松症的治疗与预防.中华骨与关节外科杂志,2015,8(5):377-384.
[23]Khan A,Dubois S,Khan AA,et al.A randomized,doubleblind,placebo-controlled study to evaluate the effects of alendronate on bone mineral density and bone remodelling in perimenopausal women with low bone mineral density.J Obstet Gynaecol Can,2014,36(11):976-982.
[24]Roberts KC,Brox WT.AAOS Clinical Practice Guideline:Management of Hip Fractures in the Elderly.J Am Acad Orthop Surg,2015,23(2):138-140.
[25]Cosman F,de Beur SJ,Le Boff MS,et al.Clinician's Guide to Prevention and Treatment of Osteoporosis.Osteoporos Int,2014,25(10):2359-2381.
[26]Larsen ER,Mosekilde L,Foldspang A.Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents:a pragmatic population-based 3-year intervention study.J Bone Miner Res,2004,19(3):370-378.
[27]Moyer VA,U.S.Preventive Services Task Force.Vitamin D and calcium supplementation to prevent fractures in adults:U.S.Preventive Services Task Force recommendation statement.Ann Intern Med,2013,158(9):691-696.
[28]Avenell A,Mak JC,O'Connell D.Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men.Cochrane Database Syst Rev,2014,4:CD000227.
[29]Papadimitropoulos E,Wells G,Shea B,et al.Meta-analyses of therapies for postmenopausal osteoporosis.ysis of the efficacy of vitamin D treatment iⅧ:Metaanaln preventing osteoporosis in postmenopausal women.Endocr Rev,2002,23(4):560-569.
[28]中华人民共和国国家卫生和计划生育委员会.《国家基本药物目录》(2012年版).2013-05-01.
[2]Mao H,Zou J,Geng D,et al.Osteoporotic vertebral fractures without compression:key factors of diagnosis and initial outcome of treatment with cement augmentation.Neuroradiology,2012,54(10):1137-1143.
[3]胡侦明,杨惠林,王根林,等.经皮椎体成形术治疗的相关建议.中华骨与关节外科杂志,2015,8(5):375-376.
[4]Parker M,Johansen A.Hip fracture.BMJ,2006,333(7557):27-30.
[5]L?nnroos E,Kautiainen H,Karppi P,et al.Incidence of second hip fractures.A population-based study.Osteoporos Int,2007,18(9):1279-1285.
[6]Black DM,Delmas PD,Eastell R,et al.Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.N Engl J Med,2007,356(18):1809-1822.
[7]Black DM,Reid IR,Boonen S,et al.The effect of 3 versus6 years of zoledronic acid treatment of osteoporosis:a randomized extension to the HORIZON-Pivotal Fracture Trial(PFT).J Bone Miner Res,2012,27(2):243-254.
[8]Black DM,Reid IR,Cauley JA,et al.The effect of 6 versus9 years of zoledronic acid treatment in osteoporosis:a randomized second extension to the HORIZON-Pivotal Fracture Trial(PFT).J Bone Miner Res,2015,30(5):934-944.
[9]Lyles KW,Colón-Emeric CS,Magaziner JS,et al.Zoledronic acid and clinical fractures and mortality after hip fracture.N Engl J Med,2007,357(18):1799-1809.
[10]Black DM,Schwartz AV,Ensrud KE,et al.Effects of continuing or stopping alendronate after 5 years of treatment:the Fracture Intervention Trial Long-term Extension(FLEX):a randomized trial.JAMA,2006,296(24):2927-2938.
[11]Bone HG,Hosking D,Devogelaer JP,et al.Ten years'experience with alendronate for osteoporosis in postmenopausal women.N Engl J Med,2004,350(12):1189-1199.
[12]Zhang ZL,Liao EY,Xia WB,et al.Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women:a 6-month,randomized,open-label,active-comparator-controlled study with a6-month extension.Osteoporos Int,2015,26(9):2365-2374.
[13]Black DM,Thompson DE,Bauer DC,et al.Fracture risk reduction with alendronate in women with osteoporosis:the Fracture Intervention Trial.J Clin Endocrinol Metab,2000,85(11):4118-4124.
[14]Neer RM,Arnaud CD,Zanchetta JR,et al.Effect of parathyroid hormone(1-34)on fractures and bone mineral density in postmenopausal women with osteoporosis.N Engl J Med,2001,344(19):1434-1441.
[15]Fahrleitner-Pammer A,Langdahl BL,Marin F,et al.Fracture rate and back pain during and after discontinuation of teriparatide:36-month data from the European Forsteo Observational Study(EFOS).Osteoporos Int,2011,22(10):2709-2719.
[16]Chen JF,Yang KH,Zhang ZL,et al.A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia.Osteoporos Int,2015,26(1):11-28.
[17]Iwamoto J,Seki A,Sato Y,et al.Vitamin K2 promotes bone healing in a rat femoral osteotomy model with or without glucocorticoid treatment.Calcif Tissue Int,2010,86(3):234-241.
[18]Cockayne S,Adamson J,Lanham-New S,et al.Vitamin K and the prevention of fractures:systematic review and metaanalysis of randomized controlled trials.Arch Intern Med,2006,166(12):1256-1261.
[19]Huang ZB,Wan SL,Lu YJ,et al.Does vitamin K2play a role in the prevention and treatment of osteoporosis for postmenopausal women:a meta-analysis of randomized controlled trials.Osteoporos Int,2015,26(3):1175-1186.
[20]Lyritis GP,Paspati I,Karachalios T,et al.Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures.A double blind,placebo-controlled clinical study.Acta Orthop Scand Suppl,1997,275:112-114.
[21]Tsakalakos N,Magiasis B,Tsekoura M,et al.The effect of short-term calcitonin administration on biochemical bone markers in patients with acute immobilization following hip fracture.Osteoporos Int,1993,3(6):337-340.
[22]朱汉民,邱贵兴,李梅,等.原发性骨质疏松症的治疗与预防.中华骨与关节外科杂志,2015,8(5):377-384.
[23]Khan A,Dubois S,Khan AA,et al.A randomized,doubleblind,placebo-controlled study to evaluate the effects of alendronate on bone mineral density and bone remodelling in perimenopausal women with low bone mineral density.J Obstet Gynaecol Can,2014,36(11):976-982.
[24]Roberts KC,Brox WT.AAOS Clinical Practice Guideline:Management of Hip Fractures in the Elderly.J Am Acad Orthop Surg,2015,23(2):138-140.
[25]Cosman F,de Beur SJ,Le Boff MS,et al.Clinician's Guide to Prevention and Treatment of Osteoporosis.Osteoporos Int,2014,25(10):2359-2381.
[26]Larsen ER,Mosekilde L,Foldspang A.Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents:a pragmatic population-based 3-year intervention study.J Bone Miner Res,2004,19(3):370-378.
[27]Moyer VA,U.S.Preventive Services Task Force.Vitamin D and calcium supplementation to prevent fractures in adults:U.S.Preventive Services Task Force recommendation statement.Ann Intern Med,2013,158(9):691-696.
[28]Avenell A,Mak JC,O'Connell D.Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men.Cochrane Database Syst Rev,2014,4:CD000227.
[29]Papadimitropoulos E,Wells G,Shea B,et al.Meta-analyses of therapies for postmenopausal osteoporosis.ysis of the efficacy of vitamin D treatment iⅧ:Metaanaln preventing osteoporosis in postmenopausal women.Endocr Rev,2002,23(4):560-569.
[28]中华人民共和国国家卫生和计划生育委员会.《国家基本药物目录》(2012年版).2013-05-01.
基本信息:
DOI：
中图分类号:R580;R683
引用信息:
[1]邱贵兴,裴福兴,胡侦明等.中国骨质疏松性骨折诊疗指南(骨质疏松性骨折诊断及治疗原则)[J].中华骨与关节外科杂志,2015,8(05):371-374.
基金信息: